Using a blood test to guide how long immunotherapy continues for advanced melanoma
Part of Cancer, Skin clinical trials.
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have advanced melanoma (stage III or IV that cannot be surgically removed) that has spread to other parts of the body.
- You have been on an immunotherapy drug (like pembrolizumab, nivolumab, or ipilimumab plus nivolumab) for at least 6-12 months and your scans show the cancer is stable or shrinking, OR you had a serious side effect from immunotherapy that forced a pause and your doctor is deciding whether to stop treatment.
- If you have had brain metastases, you must also have tumors outside the brain.
- You are in generally good health (able to do daily activities with some help).
- You are willing to have a ctDNA blood test that guides whether to continue or stop your immunotherapy, along with regular imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with advanced cancer who have responded well to immunotherapy can safely pause their treatment, guided by a blood test that looks for cancer DNA. If the blood test stays clear, you might be able to take a break from treatment.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.